

## **IN THE CLAIMS**

1. (canceled)

2. (currently amended) A method of screening for therapeutic agents useful in the treatment of heart failure ~~a cardiovascular disease~~ in a mammal comprising the steps of

i) determining the activity of a formyl peptide receptor-like 2 (FPRL2) polypeptide in the absence of a test compound,

ii) determining the activity of said polypeptide in the presence of the test compound; and

iii) identifying the test compound as a potential therapeutic agent for the treatment of heart failure ~~a cardiovascular disease~~ if the activity of the FPRL2 polypeptide in the presence of the test compound is different than the activity of the FPRL2 polypeptide in the absence of the test compound

wherein the FPRL2 polypeptide comprises the amino acid sequence SEQ ID NO:2 or an amino acid sequence which is at least 95% homologous to SEQ ID NO:2.

3-26. (canceled)

27. (previously presented) The method of claim 26, wherein the cell is *in vitro*.

28. (previously presented) The method of claim 2, wherein the FPRL2 polypeptide is in a cell-free system.

29-31. (canceled)

32. (previously presented) The method of claim 2, wherein the FPRL2 polypeptide is in a cell.

33. (new) The method of claim 2 wherein the FPRL2 polypeptide comprises an amino acid sequence which is at least 95% homologous to SEQ ID NO:2.

34. (new) The method of claim 2 wherein the FPRL2 polypeptide comprises an amino acid sequence which is at least 98% homologous to SEQ ID NO:2.

35. (new) The method of claim 2 wherein the FPRL2 polypeptide comprises an amino acid sequence which is at least 99% homologous to SEQ ID NO:2.

36. (new) The method of claim 2 wherein the FPRL2 polypeptide comprises the amino acid sequence SEQ ID NO:2.